{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:59:34Z","timestamp":1782089974917,"version":"3.54.5"},"reference-count":40,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T00:00:00Z","timestamp":1655856000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005297","name":"Medical University of Bialystok, Poland","doi-asserted-by":"publisher","award":["SUB\/1\/DN\/19\/001\/1149"],"award-info":[{"award-number":["SUB\/1\/DN\/19\/001\/1149"]}],"id":[{"id":"10.13039\/501100005297","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Metabolites"],"abstract":"<jats:p>Psoriasis is a systemic disease that is linked to cardiometabolic complications. Paraoxonase 1 (PON1) exerts anti-atherogenic properties. Pentraxin 3 (PTX3) is related to heart failure and atherosclerosis. We aimed to evaluate the protein levels in psoriatic patients and explore possible relations with disease activity, metaflammation parameters and systemic treatment. Thirty-three patients with plaque-type psoriasis and eleven healthy controls were enrolled in the study. Blood samples were collected before and after three months of therapy with acitretin or methotrexate. Serum proteins levels were evaluated using Bio-Plex 200 System. The mean serum pentraxin 3 level was significantly higher in patients with psoriasis, compared to controls (p &lt; 0.01). Significant negative correlations between PTX3 with triglycerides in overweight patients, with glucose, cholesterol and triglycerides in obese patients, and with cholesterol and triglycerides in severe psoriatics were noted (all p &lt; 0.05). After the treatment, PTX3 significantly decreased (p &lt; 0.05). The mean serum PON1 in psoriatic patients did not differ, compared to the controls (p &gt; 0.05). In psoriatics of normal weight, PON1 correlated negatively with liver enzymes activity (p &lt; 0.05). PTX3 might exert a protective role in terms of cardiometabolic disorders development, especially in overweight and obese or most severe psoriatics. PON1 could serve as an indicator of the liver disorders in psoriasis.<\/jats:p>","DOI":"10.3390\/metabo12070580","type":"journal-article","created":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T23:11:19Z","timestamp":1655939479000},"page":"580","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Potential Predictive Value of Serum Pentraxin 3 and Paraoxonase 1 for Cardiometabolic Disorders Development in Patients with Psoriasis\u2014Preliminary Data"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8018-9960","authenticated-orcid":false,"given":"Anna","family":"Baran","sequence":"first","affiliation":[{"name":"Department of Dermatology and Venereology, Medical University of Bialystok, Zurawia 14 St., 15-540 Bialystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1414-4569","authenticated-orcid":false,"given":"Anna","family":"Stepaniuk","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, Medical University of Bialystok, Zurawia 14 St., 15-540 Bialystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulina","family":"Kiluk","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, Medical University of Bialystok, Zurawia 14 St., 15-540 Bialystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8688-4171","authenticated-orcid":false,"given":"Tomasz W.","family":"Kaminski","sequence":"additional","affiliation":[{"name":"Pittsburgh Heart, Lung and Blood Vascular Medicine Institute, University of Pittsburgh, Pittsburgh, PA 15260, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Maciaszek","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Hepatology, Medical University of Bialystok, Zurawia 14 St., 15-540 Bialystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iwona","family":"Flisiak","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, Medical University of Bialystok, Zurawia 14 St., 15-540 Bialystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,6,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Dastoli, S., Nistic\u00f2, S.P., Morrone, P., Patruno, C., Leo, A., Citraro, R., Gallelli, L., Russo, E., De Sarro, G., and Bennardo, L. (2022). Colchicine in Managing Skin Conditions: A Systematic Review. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14020294"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Amoruso, G.F., Nistic\u00f2, S.P., Iannone, L., Russo, E., Rago, G., Patruno, C., and Bennardo, L. (2021). Ixekizumab May Improve Renal Function in Psoriasis. Healthcare, 9.","DOI":"10.3390\/healthcare9050543"},{"key":"ref_3","first-page":"3453","article-title":"The levels of serum pentraxin3, CRP, fetuin-A, and insulin in patients with psoriasis","volume":"18","author":"Uysal","year":"2014","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Baran, A., Nowowiejska, J., Kami\u0144ski, T.W., Krahel, J.A., and Flisiak, I. (2021). Circulating MAdCAM-1 and ITGB7 in patients with plaque psoriasis and eruptive lichen planus\u2014Preliminary data. Biology, 10.","DOI":"10.3390\/biology10111129"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/jcla.20471","article-title":"Serum paraoxonase-1 activities and oxidative status in patients with plaque-type psoriasis with\/without metabolic syndrome","volume":"25","author":"Usta","year":"2011","journal-title":"J. Clin. Lab. Anal."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/jcla.21850","article-title":"Serum Visfatin, Fetuin-A, and Pentraxin 3 Levels in Patients With Psoriasis and Their Relation to Disease Severity","volume":"30","author":"Okan","year":"2016","journal-title":"J. Clin. Lab. Anal."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Baran, A., Kiluk, P., Nowowiejska, J., Kami\u0144ski, T., Maciaszek, M., and Flisiak, I. (2022). Galectin-3 as a novel multifaceted and not only cardiovascular biomarker in patients with psoriasis with regard to systemic treatment\u2014Preliminary data. Biology, 11.","DOI":"10.3390\/biology11010088"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Krahel, J.A., Baran, A., Kaminski, T.W., Maciaszek, M., and Flisiak, I. (2020). Methotrexate Decreases the Level of PCSK9-A Novel Indicator of the Risk of Proatherogenic Lipid Profile in Psoriasis. The Preliminary Data. J. Clin. Med., 9.","DOI":"10.3390\/jcm9040910"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.cbi.2016.05.036","article-title":"Paraoxonases-1, -2 and -3: What are their Functions?","volume":"259","author":"Furlong","year":"2016","journal-title":"Chem. Biol. Interact."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1179\/1351000213Y.0000000061","article-title":"Evaluation of systemic oxidant\/antioxidant status and paraoxonase 1 enzyme activities in psoriatic patients treated by narrow band ultraviolet B phototherapy","volume":"18","author":"Pektas","year":"2013","journal-title":"Redox Rep."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Meneses, M.J., Silvestre, R., Sousa-Lima, I., and Macedo, M.P. (2019). Paraoxonase-1 as a Regulator of Glucose and Lipid Homeostasis: Impact on the Onset and Progression of Metabolic Disorders. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20164049"},{"key":"ref_12","first-page":"4001","article-title":"Evaluation of serum paraoxonase level and dyslipidemia in psoriasis","volume":"4","author":"Prathibha","year":"2016","journal-title":"Int. J. Res. Med. Sci."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1179\/1351000213Y.0000000071","article-title":"Paraoxonase 1 in neurological disorders","volume":"19","author":"Menini","year":"2014","journal-title":"Redox Rep."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/j.1365-2133.2011.10539.x","article-title":"Correlation between lipoprotein(a) and lipid peroxidation in psoriasis: Role of the enzyme paraoxonase-1","volume":"166","author":"Ferretti","year":"2012","journal-title":"Br. J. Dermatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/cbf.1553","article-title":"Serum lipid profile paraoxonase and arylesterase activities in psoriasis","volume":"27","author":"Toker","year":"2009","journal-title":"Cell Biochem. Funct."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1159\/000343904","article-title":"Serum pentraxin-3 levels are associated with the severity of metabolic syndrome","volume":"22","author":"Karakas","year":"2013","journal-title":"Med. Princ. Pract."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1159\/000381879","article-title":"Serum Pentraxin-3 Level in Patients Who Underwent Coronary Angiography and Relationship with Coronary Atherosclerosis","volume":"24","author":"Nerkiz","year":"2015","journal-title":"Med. Princ. Prac."},{"key":"ref_18","first-page":"1011","article-title":"The level of FGF 21 as a new risk factor for the occurrence of cardio-metabolic disorders amongst the psoriatic patients. Preliminary data","volume":"47","author":"Kiluk","year":"2008","journal-title":"Int. J. Dermatol."},{"key":"ref_19","first-page":"298019","article-title":"Evaluation of the association of plasma pentraxin 3 levels with type 2 diabetes and diabetic nephropathy in a Malay population","volume":"2013","author":"Seman","year":"2013","journal-title":"J. Diabetes Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/joim.12411","article-title":"Association between levels of pentraxin 3 and incidence of chronic kidney disease in the elderly","volume":"279","author":"Qureshi","year":"2016","journal-title":"J. Intern. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1111\/j.1365-4632.2008.03666.x","article-title":"Goeckerman\u2019s therapy for psoriasis with special reference to serum pentraxin 3 level","volume":"47","author":"Ctirad","year":"2008","journal-title":"Int. J. Dermatol."},{"key":"ref_22","first-page":"415","article-title":"Long pentraxin 3: A marker of inflammation in untreated psoriatic patients","volume":"18","author":"Bevelacqua","year":"2006","journal-title":"Int. J. Mol. Med."},{"key":"ref_23","first-page":"177","article-title":"Pentraxin 3 as a Marker for Cardiovascular Disease Risk in Overweight and Obese Children","volume":"37","author":"Dervisoglu","year":"2021","journal-title":"Acta Cardiol. Sin."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1007\/s12325-020-01346-6","article-title":"Psoriasis and Cardiovascular Risk: A Comprehensive Review","volume":"37","author":"Masson","year":"2020","journal-title":"Adv. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Ram\u00edrez-Ter\u00e1n, A.L., Vega-Memije, M., Torres-Tamayo, M., and Mart\u00ednez-Alvarado, M. (Arch. Cardiol. Mex., 2021). Carotid intima-media thickness in patients with psoriasis with and without metabolic syndrome, Arch. Cardiol. Mex., Online ahead of print.","DOI":"10.24875\/ACME.M22000339"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2147\/VHRM.S164274","article-title":"Serum markers for asymptomatic atherosclerosis in Egyptian psoriatic patients: Study controlled by Doppler estimation of carotid intima-media thickness","volume":"14","author":"Sabry","year":"2018","journal-title":"Vasc. Health Risk Manag."},{"key":"ref_27","first-page":"4112","article-title":"PTX3 expression in the plasma of elderly ACI patients and its relationship with severity and prognosis of the disease","volume":"20","author":"Qin","year":"2016","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Deyab, G., Hokstad, I., Whist, J., Sm\u00e5stuen, M.C., Agewall, S., Lyberg, T., Bottazzi, B., Meroni, P., Leone, R., and Hjeltnes, G. (2017). Anti-rheumatic treatment is not associated with reduction of pentraxin 3 in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0169830"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.etp.2011.07.003","article-title":"Pentraxin 3 as a potential biomarker of acetaminophen-induced liver injury","volume":"65","author":"Yaman","year":"2013","journal-title":"Exp. Toxicol. Pathol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"6773","DOI":"10.1038\/s41598-021-86231-0","article-title":"Paraoxonase 1 concerning dyslipidaemia, cardiovascular diseases, and mortality in haemodialysis patients","volume":"11","author":"Grzegorzewska","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_31","first-page":"1314623","article-title":"Cardiovascular Insufficiency, Abdominal Sepsis, and Patients\u2019 Age Are Associated with Decreased Paraoxonase-1 (PON1) Activity in Critically Ill Patients with Multiple Organ Dysfunction Syndrome (MODS)","volume":"2019","author":"Lesnik","year":"2019","journal-title":"Dis. Markers"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.clinbiochem.2011.08.007","article-title":"Evaluation of serum paraoxonase and arylesterase activities in patients with psoriasis and its relationship with serum lipid profile","volume":"44","author":"Khoshnoodi","year":"2011","journal-title":"Clin. Biochem."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1161\/CIRCRESAHA.118.313608","article-title":"Association Between Oxidation-Modified Lipoproteins and Coronary Plaque in Psoriasis: An Observational Cohort Study","volume":"123","author":"Sorokin","year":"2018","journal-title":"Circ. Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12944-016-0388-z","article-title":"Myeloperoxidase-oxidized high density lipoprotein impairs atherosclerotic plaque stability by inhibiting smooth muscle cell migration","volume":"16","author":"Zhou","year":"2017","journal-title":"Lipids Health Dis."},{"key":"ref_35","first-page":"39","article-title":"Inflammation and Vascular Calcification Causing Effects of Oxidized HDL are Attenuated by Adiponectin in Human Vascular Smooth Muscle Cell","volume":"8","author":"Harun","year":"2019","journal-title":"Int. J. Mol. Cell. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1194\/jlr.P030601","article-title":"Dietary cholesterol increases paraoxonase 1 enzyme activity","volume":"53","author":"Kim","year":"2012","journal-title":"J. Lipid Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1111\/j.1365-2133.2012.11170.x","article-title":"Paraoxonase 1 (PON1) 55 polymorphism, lipid profiles and psoriasis","volume":"167","author":"Asefi","year":"2012","journal-title":"Br. J. Dermatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s00403-013-1366-1","article-title":"Effect of the systemic use of methotrexate on the oxidative stress and paraoxonase enzyme in psoriasis patients","volume":"305","author":"Kilic","year":"2013","journal-title":"Arch. Dermatol. Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1111\/bjd.12144","article-title":"Oxidative stress and psoriasis: The effect of antitumour necrosis factor-alpha inhibi-tor treatment","volume":"168","author":"Bacchetti","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/art.39833","article-title":"Improvement in HDL Function in Early Rheumatoid Arthritis Patients Treated with Methotrexate Monotherapy or Combination Therapy in the TEAR Trial","volume":"69","author":"Lee","year":"2017","journal-title":"Arthritis Rheumatol."}],"container-title":["Metabolites"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-1989\/12\/7\/580\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:37:59Z","timestamp":1760139479000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-1989\/12\/7\/580"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,22]]},"references-count":40,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,7]]}},"alternative-id":["metabo12070580"],"URL":"https:\/\/doi.org\/10.3390\/metabo12070580","relation":{},"ISSN":["2218-1989"],"issn-type":[{"value":"2218-1989","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,22]]}}}